Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Leon Kircik, Dermatology Meeting News 2021: Roflumilast Foam in Scalp and Body Psoriasis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 19th 2021

Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and body psoriasis.

His abstract entitled ‘Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A Randomized, Double-blind, Vehicle-controlled Phase 2b Study’ was presented at AAD VMX, 23-25 April.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.  

Questions

  1. Can you give us a brief overview of scalp psoriasis, its disease burden and the unmet needs in its treatment? (0:20)
  2. Could you tell us a little about roflumilast and the aim of your study? (1:10)
  3. Could you tell us about the design and patient population enrolled in your phase 2b study? (1:33)
  4. What were the key clinical endpoints measured in the study? (2:17)
  5. Could you briefly summarize the overall results? (2:28)

Disclosures: Prof. Leon Kircik is a speaker for Galderman, Genetech, Johnson & Johnson, Leo Pharma, 3M Pharmaceuticals, Onset Dermatologics, Pharmaderm, Merck Serano, SkinMedica, Stiefel a GSK company, Triax Pharmaceuticals, Valeant Pharmaceuticals, Warner Chilcott; serves on an advisory board for Galderma, Genetech, Intendis, Johnson & Johnson, NanoBio Corporation, Promius Pharma, LLC, SkinMedica, Stiefel a GSK company, Valeant Pharmaceuticals, Warner Chilcott; is an investigator for Ferndale Laboratories, Galderman, Genetech, GlaxoSmithKline, Healthpoint, Intendis, Johnson & Johnson, Leo Pharma, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, NanoBio Corporation, Novartis Pharmaceuticals, Nucryst, Obagi Medical Products, Onset Dermatologics, Orthro Dermatologics, Promius Pharma, LLC, QLT Inc, Pharmaderm, Pfizer, SkinMedica, Stiefel a GSK company, TolerRx, Triax Pharmaceuticals, LLC, Valeant Pharmaceuticals, Warner Chilcott; is a consultant for Galderma Laboratories, Genetech, Intendis, Johnson & Johnson, Leo Pharma, Medical International Technologies, Merck & Co, Merz Pharmaceuticals, Novartis, Promius Pharma, PuraCap Pharmacetical, SkinMedica, Stiefel a GSK company, Triax Pharmaceuticals, Valeant Pharmaceutical.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.

Filmed in coverage of the AAD VMX 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup